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It is estimated that one third of the world’s adult population, and around 1.1 billion individuals, smokes tobacco, which 
makes every sixth human being a smoker.1 
Smoking-related illness is estimated to cause ~ 5 
million deaths per annum around the globe, but is 
considered a leading preventable cause of death.2 
In developed countries, the rates of smoking have 
either leveled off or declined, but smoking-related 
deaths are on the rise in developing countries 
and are most common among the least-educated 
people. Initially, cigarette smoking prevalence was 
higher in males, but since the 1980s the gender gap 
has narrowed and plateaued.3 
In 2003, in a school-based cross-sectional 
survey on water pipe-based tobacco smoking 
(sheesha) in Oman, 1,962 students were interviewed 
(26.6% were ever-smokers and 9.6% were current 
smokers). Among the current smokers, 15.5% were 
males and only 2.6% were females.4 In the USA in 
2009, approximately 20.6% of adults and nearly 20% 
of high school students were cigarette smokers. 
An estimated 9% of them were smokeless tobacco 
consumers. Smokeless tobacco products include 
products such as moist snuff, chewing tobacco, 
snus (moist powdered tobacco) and dissolvable 
nicotine products such as strips and sticks. Current 
evidence, however, does not support the opinion 
that the use of these products is safer than smoking. 
Additionally, there is substantial evidence that these 
products can be implicated in oral and pancreatic 
cancers, precancerous oral lesions, gingival 
recession, gingival bone loss around the teeth, 
tooth-staining, and nicotine addiction.5,6
In the USA, tobacco use is responsible for nearly 
1 in 5 deaths.7 In 2012, the estimated percentage 
of new lung cancers in males (116,470 cases) and 
females (109,690 cases) was 14% each. Among these 
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امللخ�ص: على مدى ال�شنوات كان تدخني التبغ ال�شبب االأكرث ر�شوخا لعمليات الت�رسطن الرئوي وغريها من االأمرا�س ال�شدرية. وعلى مدى 
اخلم�شني عاما املا�شية ، حدث تطور يف عملية �شقل التبغ وتر�شيحه مما ت�شبب بتغري يف نوع ال�رسطان الرئوي ، حيث اأ�شبح ال�رسطان 
الغدي هو النوع االأكرث انت�شارا. وقد برز التدخني باعتباره نذير متنبئ قوي خل�شائ�س املر�س جنبا اإىل جنب مع غريها من املتغريات.  
 ويف هذا املقال ن�شتعر�س باإيجاز احلقائق العلمية حول التبغ وكيفية حدوث �رسطان الرئة يف املدخنني وغري املدخنني ، كما �شن�شتعر�س 
اأي�شا نتائج عالج �رسطان الرئة يف التجارب ال�رسيرية املختلفة.
مفتاح الكلمات: تدخني التبغ؛ ال�شجائر؛ اأورام الرئة؛ النيكوتني؛ الربوتني االلتحامي؛ اإن�شاين؛ اجلني؛ امل�شتقبل؛ عامل منو الب�رسة؛ امل�رسطنات.
abstract: Tobacco smoking remains the most established cause of lung carcinogenesis and other disease 
processes. Over the last 50 years, tobacco refinement and the introduction of filters have brought a change in 
histology, and now adenocarcinoma has become the most prevalent subtype. Over the last decade, smoking 
also has emerged as a strong prognostic and predictive patient characteristic along with other variables. This 
article briefly reviews scientific facts about tobacco, and the process and molecular pathways involved in lung 
carcinogenesis in smokers and never-smokers. The evidence from randomised trials about tobacco smoking’s 
impact on lung cancer outcomes is also reviewed.
Keywords: Tobacco Smoking; Lung Neoplasms; Nicotine; EML4 ALK fusion protein, human; K-Ras Gene; 
Receptor, Epidermal Growth Factor; Carcinogens. 
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lists in reviews and original papers were scanned 
for further sources of information. Only English 
language articles were searched.
Tobacco
Tobacco is processed from the leaves of plants in 
the genus Nicotiana.12 Besides its use as a drug, the 
tobacco plant is also used in bioengineering and as 
an ornamental plant. For many developed as well 
as developing countries, it remains a valuable cash 
crop.
Nicotiana tabacum and rustica are considered 
the main commercial species, with alkaloid nicotine 
as the addictive constituent of tobacco responsible 
for its tolerance and dependence; however, it is not a 
carcinogen.13,14 After harvest, tobacco is cured over 
many days, allowing slow oxidation and degradation 
of the constituent carotenoids. This allows for the 
‘smoothness’ of the smoke, giving cured tobacco its 
aromatic flavours. 
After curing, tobacco is moved to a storage 
area for processing. For the intact plants, the leaves 
are removed from the tobacco stalks in a process 
called stripping, which makes the smoke milder and 
more inhalable. Tobacco is subsequently packed 
into various forms for consumption (i.e. smoking, 
chewing, snuffing, etc.) It is the cured tobacco 
which is easily inhalable and causes lung cancer and 




Certain patient characteristics have consistently 
shown an impact on lung cancer outcomes. For 
example, lung cancer is a disease of the elderly, 
although advancing age was not a prognostic 
factor for survival but high scores on the Charlson 
Comorbidity Index (CCI) were a factor. Taken 
together, toxicity, age and high CCI scores were 
significant predictors.16 The incidence of lung 
cancer is higher among men (34%) as compared 
to women (13.5%). The age-standardised ratio for 
cancer incidence is 33.81%, and for mortality is 
29.2% in men alone.17 
In the past, the incidence was lower in females, 
but worldwide it is now the fourth most frequent 
lung cancers, 29% of male and 26% of female cases 
were estimated to be fatal.3 Smoking accounts for 
at least 30% of all cancer deaths and 87% of lung 
cancer deaths.8 
Cases of small-cell lung carcinoma (SCLC) 
cancer in never-smokers are exceptionally rare. 
Active smoking also increases the risk of numerous 
other cancers, including those of the nasal passages, 
sinuses, oral cavity, upper aerodigestive tract, 
pancreas, gynaecological system, kidney, bladder, 
stomach, colorectum and acute myeloid leukaemia.9 
The World Health Organization (WHO) has 
published guidelines to measure smoking, and 
classifies individuals as smokers, non-smokers, or 
ever-smokers, and then establishes further sub-
categories.10
Passive smoking, or environmental tobacco 
smoke, is also classified as a known human 
carcinogen and is considered the cause of ~50,000 
deaths annually. Passive smoking is a mixture of two 
forms of smoke from burning tobacco: sidestream 
smoke, which comes from the end of a lighted 
source (cigarette, pipe, or cigar), that contains 
smaller particles which easily make their way into 
the cells and is rich in carcinogens, and the main-
stream smoke which is exhaled by a smoker.11 
Methods
To find relevant information and articles, searches 
were made on PubMed, Google, Clinical-trials.
gov, the Cochrane Library, abstracts of the World 
Conference for Lung Cancer, and the annual 
meetings of the American Society of Clinical 
Oncology (ASCO) and the European Society for 
Medical Oncology (ESMO). Online abstracts and 
full articles were also accessed from the National 
Library of Medicine (NLM) catalogue, including 
journals referenced in the National Center for 
Biotechnology Information (NCBI) database: 
Journal of Clinical Oncology, Lancet, Cancer, Lung 
Cancer, Clinical Lung Cancer, New England Journal 
of Medicine, Clinics, Cancer Research, Journal of 
Thoracic Oncology, Journal of the National Cancer 
Institute, Expert Review of Molecular Diagnostics, 
Cancer Epidemiology, Biomarkers & Prevention, 
Clinician Reviews, and CA: A Cancer Journal for 
Clinicians. The medical subjects heading (MeSH) 
terms were searched to confirm keywords. In 
addition to computer-based searches, the reference 
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cancer in women (516,000 cases; 8.5% of all 
cancers) and the second most common cause of 
cancer deaths (427,000 deaths; 12.8% of the total).18 
The highest incidence rate in women is observed 
in North America, where lung cancer is now the 
second most frequent cancer in women. This is 
attributed to smoking. It is the lowest in central 
Africa, where it is the 15th most frequent cancer 
in women. As one in 5 women who develop lung 
cancer is a never-smoker, it remains a mystery as to 
what exactly causes their cancer. 
Lung cancer in never-smokers is proposed to 
be due to multiple risk factors, including genetic 
predisposition—although this is exceedingly rare 
(1% with >3 affected relatives). Genetics mutations 
remain an underlying cause as we do encounter 
lung cancer at a relatively earlier age when it runs 
in families. Among the first studies revealing a 
genetic link was one conducted over 40 years ago 
by Tokuhata et al.19 The study revealed that never-
smokers with lung cancer were 40% more likely 
than never-smoking controls to report a first degree 
relative with lung cancer. Women were more likely 
to report such a family history and 10–15% had at 
least one first-degree relative with the disease.
In a landmark hormonal therapy study of 
16,608 post-menopausal females, the risk of 
developing non-small-cell lung cancer (NSCLC) 
was not significant (P 0.21) in the experimental arm 
(treatment with oestrogen/medroxyprogesterone 
acetate) compared to the placebo group; however, 
after a follow-up of 5 years a divergence emerged, 
with more lung cancer diagnoses in the treatment 
arm. In addition, these females had poorly-
differentiated tumours and a higher incidence of 
metastatic disease. There was a 30% increase in 
cardiovascular events, a 26% increase in breast 
cancer, and a 40% increase in cerebral vascular 
accidents (CVAs) compared to the placebo group. 
The hormonal treatment of postmenopausal 
women did not increase incidence of lung cancer, 
yet, it increased the lung cancer specific mortality, 
in particular deaths from NSCLC.20 
Passive, or second-hand smoke from a spouse, 
friends, roommates, or childhood exposure from 
parents; vehicle or factory exhausts; cooking 
fumes in poorly ventilated kitchens; residence in 
mountainous areas (radon A, B, and C exposure), 
and occupational exposure or environmental toxins 
(asbestos and arsenic), have all been implicated in 
lung carcinogenesis.
Certain occupations are also associated with a 
higher risk of developing lung cancer (e.g. miners, 
asbestos workers, glass manufacturers, painters, 
printers and masonry workers). Many occupational 
substances carry a substantial risk, e.g. diesel and 
welding fumes, motor exhaust, natural fibres 
(asbestos, silica, wood, or coal dust), radon, 
reactive chemicals (mustard gas, vinyl chloride) 
and solvents (benzene, toluene). Adenocarcinoma 
subtypes are also associated with subpleural 
scars secondary to chronic inflammation (e.g. old 
infarcts, healed granuloma or pneumonitis and 
post-traumatic scars).21 C-reactive protein (CRP) 
levels were documented to be higher in NSCLC in 
a study suggestive of an aetiologic role of chronic 
inflammation in NSCLC carcinogenesis.
Females with lung cancer tend to live longer 
compared to men because of diagnosis at a younger 
age, possibly diagnosis at an earlier stage, having 
adenocarcinoma more frequently, and perhaps due 
to inherent longevity. It is also possible that their 
superior survival in lung cancer is due to differences 
in nicotine metabolism, cytochrome P-450 enzymes 
and lifestyle.22–24 
Tobacco Metabolism
Tobacco carcinogens are metabolised by 
cytochrome P-450 enzymes to make them 
readily excretable. Lipoxygenase, cyclooxygenase, 
myeloperoxidases, and monoamine oxidases may 
also be involved, although infrequently. The 
oxygenated intermediate metabolites undergo 
subsequent transformations (detoxification 
and secretion) by glutathiones, sufatases,or 
uridine-5’-diphosphate-glucuronosyltransferases 
(U5'DPGT).25 A few of the metabolites 
generated during these processes react with the 
deoxyribonucleic acid (DNA) to form covalent 
binding products called DNA adducts in a 
process called metabolic activation. Carcinogens 
like polcyclic aromatic hydrocarbons (PAH) and 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) require metabolic activation to exert their 
carcinogenic effects. The carcinogenic metabolites 
of PAH-benzopyrenes (i.e. 7,8 diol 9,10 epioxides) 
and nicotine-derived nitrosamine ketone (NNK 
or NNAL) react with DNA to form adducts. 
Alpha-hydroxylase converts methyl adducts from 
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[HR] 0.87; P <0.001) is considered to be associated 
with poorer survival.29 In the E1594 trial, patients 
without weight loss (<10%) had superior survival.27 
Weight loss results from the release of cytokines 
(IL-6, IL-1β, interleukin-1RN, and tumour necrosis 
factor) with the contribution of anorexia, nausea, 
vomiting, diarrhoea, mediastinal lymphadenopathy 
compromising food passages, cytotoxic therapy 
and concurrent illness. The severity or burden 
of comorbidity has also been reported to have a 
clear relationship with poor survival in a variety of 
cancers, including lung cancer.30
Tobacco Smoking and 
Lung Cancer
Smoking is strongly linked with SCLC) and 
squamous-cell carcinoma (SCC). There has 
been a gradual change in the way cigarettes are 
manufactured which has resulted in a shift in the 
histology from SCC which was more frequent 
in the 1970s to adenocarcinoma subtypes 
which are currently more frequent. The impact 
of low tar cigarettes, introduced in the 1950s, 
on adenocarcinoma rates has been due to the 
introduction of filter vents in these cigarettes, 
making it easier for the smoker to draw in smoke, 
and allowing deeper inhalation than older, 
unfiltered cigarettes. Inhalation transports tobacco-
specific carcinogens more distally toward the 
bronchoalveolar junction where adenocarcinoma 
often arises. Secondly, blended reconstituted 
tobacco releases a higher concentration of 
N-nitrosamines from tobacco stems.31 A relatively 
older estimate of more than 26,000 cases from 17 
published reports suggests that the adenocarcinoma 
to SCC ratio is approximately 0.4 in lung cancers 
in smokers as compared to 3.4 in never-smokers.32 
Lung cancer risk increases with the duration and 
the former agent to form 7-methylguanine or O6 
methylguanine. The damage may be repaired, or 
apoptosis may ensue. Miscoding may result in 
permanent mutations, including K-Ras, p53, p16, 
fragile histidine triad protein (F-HIT), or unknown 
mutations, which results in either the suppression 
of tumour suppressor genes or the activation of 
oncogenes. Not all smokers get lung cancer, but 
under 20% do. Susceptibility to the development 
of cancer depends on the balance between 
metabolic activation and detoxification of potential 
carcinogens in smokers [Figure 1].25
Poor patient performance status (PS) is also 
associated with poorer survival outcomes. The 
absolute benefit of chemotherapy in metastatic 
disease at one year varied according to the PS. In 
PS 0 and 1, the absolute benefit was 8%. In PS 2, the 
benefit was 5%, while in PS 3 it was 4%.26 Median 
survival fell inversely with increasing PS in the 
Eastern Cooperative Oncology Group (ECOG) 
E1549 trial [Table 1].27 
Race is also prognostic with lung cancer risk 
varying between different races and ethnicities. In 
the USA, age-adjusted Surveillance, Epidemiology 
and End Results (SEER) incidence rates for lung 
cancer in Afro-Americans and Caucasians are higher 
compared to Alaskans, Indians, Asians, Pacific 
Islanders and Hispanics.28 Weight loss (hazard ratio 
Table 1: Survival difference by performance status and 
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ECOG = Eastern Cooperative Oncology Group; PS = performance 
status.
 
Figure 1: Link between nicotine addiction and lung cancer via tobacco smoke carcinogens and carcinogenesis. 
Adapted from: Hecht SS. Tobacco smoke carcinogens and lung cancer.25
7-MG, 06-MG = 7-methylguanine, 06-methylguanine; DNA = dioribonucleic acid; NER = nucleoside excision repair; BER = base excision repair.
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Prevalence of subtypes of lung cancer in smokers and 
never-smokers (52 patients) at SQUH
SCC 91 9
Adenocarcinoma 61 39
Undifferentiated CA 33 -
SClC 66.7 33.3
Source: Hecht SS. Tobacco carcinogens, their biomarkers and tobacco 
induced cancer.83
SCC = squamous-cell carcinoma; NOS = not otherwise specified; BAC 
= bronchioalveolar carcinoma; SQUH = Sultan Qaboos University 
Hospital; CA = cancer; SCLC =  small-cell lung carcinoma.
intensity of tobacco consumption [Figure 2].33 Table 
2 illustrates the prevalence of various subtypes of 
lung carcinoma in smokers and never-smokers.
Approximately 20 potential carcinogens of 
~3,500 chemicals have been detected in aburning 
cigarette. The most established are the polycyclic 
aromatic hydrocarbons (PAH) like benzo(a)
pyrenes, and the tobacco-specific N-nitrosamine 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK), while others include Asz-arenes, 
Dibenz(a,h)acridine, inorganic compounds like 
cadmium, chromium, nickel, arsenic, radioactive 
polonium (Po210) and organic compounds like 
butadiene.32 Nitrates in the tobacco are reduced to 
NH2– and NH3 while smoking. Air-cured tobacco 
contains higher concentrations of aromatic amines 
as compared to flue-cured tobaccos (e.g. the 
urinary bladder carcinogens β2-naphthylamine and 
4-aminobiphenyl).34
Cigarette smoke contains high levels of acrolein, 
which is toxic to the ciliated lining of the lungs, and 
other agents such as nitrogen oxides, acetaldehyde, 
phenols, and formaldehyde, which may contribute 
indirectly to pulmonary carcinogenicity in animals 
and humans.35 
Cigarette smoke also contains free radicals 
(FR) (e.g. hydrogen peroxide [H2O2], hydroxyl ion 
[OH–], sulfoxide anion) which induce oxidative 
damage in animal models as well as humans, while 
catechol and hydroquinone play their roles in 
single strand DNA breaks caused by the release of 
FR.24 However, the evidence for the latter remains 
relatively low due to negative trials of anti-oxidant 
therapy in humans. Total NNAL and cotinine 
(nicotine metabolite) were measured in urine from 
smokers. The highest tertiles exhibited an 8.5-fold 
increased risk for lung cancer relative to those 
smokers with a comparable smoking history but 
possessing the lowest tertiles of these metabolites. 
These findings directly link NNK exposure to lung 
cancers in humans.36
Smoking has multidimensional effects on 
lung cancer [Figure 3]. Tobacco smoking remains 
the most consistent causative agent in lung 
carcinogenesis in animal and human models, yet, 
over the past decade or so, it has also emerged as 
a prognostic and predictive clinical characteristic. 
Proto-oncogenes, 
Oncogenes, and Cellular 
Pathways in Malignant 
Transformation
Malignant transformation involves certain genetic 
and epigenetic changes such as hypomethylation, 
and methylation of the cytosine guanine promoter 
region (CpG) leading to the silencing of tumour 
suppressor genes. Generally, hereditary genetic 
defects lead to the relatively early onset of cancers, 
 
Figure 2: Relative risk of lung cancer, according to 
duration and intensity of smoking, men.
Adapted from Cancer Research UK. Tobacco and cancer risk 
statistics.33
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4-anaplastic lymphoma kinase fusion gene [EML4 
ALK] in lung cancer).38 Proto-oncogenes are turned 
off once the embryogenesis and developmental 
processes they regulate are completed. However, in 
cancer, proto-oncogene activity remains high, or is 
inappropriately reactivated later in life.39
In order to grow and divide, cells respond to 
outside signals through the binding of extracellular 
ligands (growth factors) to the extracellular region 
of certain trans-membrane receptors, such as 
EGFR. When a ligand binds to a cell receptor, the 
receptor will frequently undergo a transformational 
change in its shape, which in turn leads to activation 
of tyrosine kinase (TK) activity in the intracellular 
domain and propagates the cell signal transduction 
pathways which regulate cell growth, proliferation, 
angiogenesis, apoptosis or cell death.40 In cancer, 
these processes may become autonomous due to 
overexpression of these receptors by virtue of the 
genetic defects mentioned above. 
Proto-oncogenes may also code for intracellular 
proteins that normally act downstream of cell 
surface receptor pathways to stimulate cell growth 
and division. An example of this would be the 
Kirsten rat sarcoma viral oncogene homolog 
(K-Ras) in lung cancer, and some proto-oncogenes 
like cyclin D1 and E1, which normally act to push 
cells through distinct stages of the cell cycle when 
the cells receive the appropriate signals [Figure 1].39 
Inactivation of apoptotic pathways may also be a 
step towards the accumulation of abnormal cells.
Molecular Signall ing 
Pathways in Tobacco 
Smokers and Never-
Smokers
cell pathway activation in 
smokers—the smoke pathways
Smokers have their own set of driver mutations 
which are distinct from lung cancer in never-
smokers.41 Common mutations in smokers include 
p53 (>50%), K-Ras (~30%), p16 (>70%), STK11 
(11%), and others like F-HIT and T790M. In 
contrast, the incidence of EGFR (4%) and EML4 
ALK mutations (2%) are relatively low in smokers 
with lung cancer. Some of these are successfully 
targeted while others are being explored as targets 
for new agents [Table 3].42
such as with hereditary colon carcinoma. On the 
other hand, sporadic genetic defects which occur 
after exposure to environmental mutagens such as 
tobacco smoke, X-γ rays, chemical, hydrocarbons, 
viruses, etc., usually appear after a latent period of 
5–20 years and therefore at older ages, such as in 
lung carcinoma. 
A proto-oncogene is a normal gene that regulates 
cell growth and differentiation and is potentially 
capable of becoming an oncogene (mutation or 
increased expression) which initiates aberrant cell 
signal transduction pathways. 
An oncogene is a modified gene which codes for 
a protein that induces a malignant transformation. 
A set of 21–25 nucleosides (miRNA) can control 
expression of these genes by downregulating them. 
Oncogenes arise as a result of a mutation in the 
proto-oncogene which increases the expression 
level or activity of the proto-oncogene, as is the case 
in point mutations, deletions or insertions. Gene 
amplification events lead to extra chromosomal 
copies of a proto-oncogene or translocation 
events that relocate a proto-oncogene to a new 
chromosomal site leading to higher expression of a 
cell surface protein receptor (e.g. epidermal growth 
factor receptor [EGFR] overexpression).37 It can 
also lead to a fusion between a proto-oncogene 
and a second gene generating a fusion protein (e.g. 
echinoderm microtubule-associated protein like 
 
Figure 3: Impact of tobacco smoke on lung cancer.
GA = general anaesthesia; Adenoca = adenocarcinoma; SCC = 
squamous-cell carcinoma; TKI = tyrosine kinase inhibitor; QoL = 
quality of life; CA = cancer; EGFRMUT = epidermal growth factor 
mutation; K-RasMUT = Kirsten rat sarcoma viral oncogene homolog 
mutation; EML4 Alk = echinoderm microtubule-associated 
protein like 4-anaplastic lymphoma kinase fusion.
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SCC = squamous-cell carcinoma; EGFR = epidermal growth factor 
receptor; TKI = tyrosine kinase inhibitor; EML4 Alk = echinoderm 
microtubule-associated protein like 4-anaplastic lymphoma kinase 
fusion gene; HER2-neu = human epidermal growth factor receptor 2; 
ROS 1 = member of subfamily of tyrosine kinase insulin receptor genes; 
K-Ras = Kirsten rat sarcoma viral oncogene homolog; TKr = tyrosine 
kinase resistance; STK11 = serine/threonine kinase 11, also known as 
liver kinase B1 (LKB1); F-HIT = fragile histidine triad protein; 
* = usually; SOX2 = SRY (sex determining region Y)-box 2; TP63 = 
tumor protein 63; PI3K = phosphatidylinositide 3 kinase AKT signal 
transducer; NRF2 = nuclear factor erythroid related factor 2.
The p53 gene is a tumour suppressor gene which 
controls the apoptotic pathways and keeps a check 
and balance on cellular proliferation and death. The 
mutation occurs in a variety of human cancers, 
including lung cancer (>50%). Point mutations 
at guanine are common. In a sample of 550 p53 
mutations in lung tumours, 33% were guanine 
(G)→thymine (T) transversions, while 26% were 
G→adenine (A) transitions. p53 mutations show 
a dose-dependent increase in G→T transversions 
at hotspots frequently after exposure to tobacco 
carcinogens. Lung cancers have a lot of overlap 
between the mutation spectrum of p53 in smokers 
and never-smokers. As a result, p53 genotyping 
cannot be used to preclude different tumours solely 
on its basis.43,44 A trial at the Massachusetts General 
Hospital investigated the p53 gene in surgically-
resected lung cancers, and found 29% of patients (n 
= 85) harbouring p53 mutations. The patients with 
p53 mutations who were current smokers were 
significantly older and had smoked for significantly 
more years (P <0.01) than those without p53 
changes. A large number (40%) of G→cytosine (C)
to T→A transversion mutations were observed 
due to increasing cumulative exposure to smoke. 
Interestingly, p53 mutations were also seen in 
patients with a history of occupational exposure to 
asbestos—5% for patients without versus 20% with 
exposure (P <0.05).45
Genes in the wide Ras gene superfamily, 
including H-Ras, N-Ras, and K-Ras oncogenes, 
on chromosome 12p12.1 encodes a family 
of membrane-localised GTP-binding proteins 
that function for TK activation and subsequent 
downstream cell signal transduction in regulating 
cell growth, differentiation, and apoptosis. The Ras 
proteins interact with multiple effectors through the 
MAPK/STAT/PI3K signalling cascades.46 Wild-type 
K-Ras has intrinsic GTPase activity, which catalyses 
the hydrolysis of bound GTP to GDP thereby 
inactivating the Ras growth-promoting signal, 
whereas oncogenic K-Ras is locked into the GTP-
bound state, leading to constitutive Ras signalling. 
Mutations in K-Ras occurred in ~43% of NSCLC 
cases in one study.42 It is common in mucinous 
adenocarcinoma, in elderly patients who are heavy 
smokers, and in earlier stages and grades, but not 
in large-cell lung cancers or bronchioloalveolar 
carcinoma (BAC). However, its frequency falls with 
stage and grade progression. The occurrence in 
never- smokers is low (~15%) and is more likely to 
be transition mutations.47 In contrast, the majority 
of mutations from tobacco smoke exposure occur 
in codons 12 (G→T transversion) and 13. 
A trial on Asian patients revealed that K-Ras 
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smokers, whereas it remains upregulated in normal 
bronchial epithelial cells from active smokers.55 
There is substantial evidence that cigarette tar and 
nitric oxide (NO) act synergistically to cause single 
strand DNA breaks.25 The lower incidence rates 
of the EGFR mutation and EML4 ALK mean that 
a smoker cannot undergo equally effective and 
possibly less toxic oral-targeted therapies. 
Cell Signall ing Pathway 
Activation in Never-
Smokers
More than 20,000 people who do not smoke tobacco 
eventually develop lung cancer in the US each 
year. Cancer in never-smokers follows different 
cell signal transduction pathways, including EGFR 
mutations in 37% (exon 21 L858R or exon 19) 
enabling targeted therapy; p53 mutations in 26%; 
human epidermal growth factor receptor 2 (HER2/ 
neu) in 2%; over-expression and activation, or a 
higher frequency for EML4 ALK fusion in 12%; 
enabling oral crizotinib (targeted) therapy through 
other unknown mutations.42,56 Never-smokers with 
higher EGFR frequency and gene copy numbers 
do well with TKI therapy, where it has shown to 
be associated with improvement in RR and PFS. 
There is a lower frequency of p53 G→C to T→A 
mutations, and lower frequency of mutations at 
hot spots. As described earlier, never-smokers have 
a lower frequency of K-Ras mutation (~15%), the 
majority of which are transition mutations with a 
lower frequency of K-Ras transversions, and low 
serine/threonine kinase 11 (STK11) mutations (also 
known as liver kinase [LBK1] mutations).47 
In a trial from East Asia of 152 never-smoking 
NSCLC patients, 75% harboured EGFR mutations, 
6% had HER2 mutations, 5% had EML4 ALK 
fusions, 2% had K-Ras mutations, 1% harboured 
ROS1 fusions, 0% had b RAF mutations, and 
10.9% had unknown mutations.57 The odds of 
an EGFR mutation are 6.5 times higher in never- 
smokers (P <0.0001), 4.4 times higher in those with 
adenocarcinoma (P <0.0001), 1.7 times higher for 
females (P 0.039), and 4–6 times higher in East 
Asians.58–63 Advanced age and acinar predominant 
subtypes were also independent predictors of EGFR 
mutations.
mutations were associated with ever-smoking 
status, male gender, and poor differentiation; 
however, Western studies have not been able to 
validate these findings.48 In the National Cancer 
Institute of Canada (NCIC) BR.21 study, 28% of 731 
patients had a K-Ras (wild) genotype that responded 
well to tyrosine kinase inhibitors (TKIs) while 15% 
had mutations that conferred primary resistance to 
targeted therapy. 
Data from the TRIBUTE trial reveals that EGFR 
and K-Ras mutations rarely occur together, and 
that survival was inferior in the group of patients 
with the K-Ras mutation who were treated with the 
addition of TKIs to chemotherapy. The presence 
of a K-Ras mutation rules out an EGFR mutation, 
and is also a marker of TKI inactivity. Patients 
harbouring the K-Ras mutation are best treated 
with chemotherapy. In a recent trial, MEK 1 and 2 
inhibitors (selumetinib), which are downstream of 
K-Ras, were given in combination with docetaxel 
and compared to docetaxel alone. The combination 
with the new agent enhanced response rates (RR) 
and progression-free survival (PFS), but overall 
survival (OS) remained only numerically superior 
in patients harbouring the K-Ras mutation.49 
LKB1/STK11 (encodes a serine-threonine 
kinase) is a tumour suppressor which negatively 
regulates mammalian target of rapamycin (mTOR) 
signalling. It is inactivated in 5–15% of primary lung 
adenocarcinomas. Homozygous deletion or loss of 
heterozygosity (LOH) of chromosome 19p at the 
LKB1 locus occurred in 90% of the tested specimen 
in primary lung cancers.50 The mutation is more 
frequent in lung cancers in smokers than never-
smokers (P 0.007), and commonly occurs with 
K-Ras mutations (P 0.042) but infrequently with 
EGFR mutations (P 0.002). T790M (substitution 
of methionine for threonine at aa position 790) in 
tumours that progress on TKIs are more common 
in smokers and ex-smokers than in never-smokers.51 
This accounts for 50% of acquired resistance to 
TKIs. Afatinib (irreversible TKI) has been approved 
as a targeted therapy against T790M.52
The p16 tumour suppressor gene is inactivated 
in >70% of human NSCLC via homozygous 
deletion or aberrant hypermethylation of the 
promoter region.53 Smoke carcinogens may also 
cause LOH and chromosomal deletions in the 
F-HIT gene.54 The downregulation of SIRT1 activity 
has also been found to be confined to lung tumours in 
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Smokers are prone to frequent side-effects 
during therapeutic courses of chemotherapy and 
radiotherapy (i.e. mucositis), and while under general 
anaesthesia (GA), and to surgical complications. 
Their post-surgical survival is also poorer. The 10-
year overall and disease-specific survival rate falls as 
the number of cigarette packs smoked increases in 
patients with surgically-resected, Stage I NSCLC.64 
Multivariate analysis from a retrospective study 
in Singapore, however, could not find a significant 
correlation between smoking and survival.65 
Smoking is also associated with poorer quality of 
life and predisposes patients to secondary cancers 
and chronic lung diseases, potentially making these 
patients unsuitable for or vulnerable to subsequent 
oncological interventions.
EGFR Mutations in Lung 
Cancer in Smokers
In a relatively older trial, most patients harbouring 
the EGFR mutation had adenocarcinomas and 
had smoked <100 cigarettes in his or her lifetime 
(never-smokers). Seven of the 15 adenocarcinomas 
resected from untreated never-smokers harboured 
the mutations, in contrast to 4 of 81 NSCLCs 
resected from untreated former or current smokers 
(P 0.0001).66 In 2004, Lynch et al. initially described 
9 patients with excellent responses to gefitinib, of 
whom 6 were never-smokers.67 Cigarette-smoking 
history was used to estimate the likelihood of 
mutations in EGFR gene exons 19 and 21 in lung 
adenocarcinomas at the Memorial Sloan Kettering 
Cancer Center (MSKCC); the mutation was 
detected in 51% of 67 never-smokers, 19% of 151 
former smokers and 4% of 47 current smokers. 
The number of packs smoked per year (more than 
15 packs/year, P <0.001) and smoke-free years 
(smoking cessation less than 25 years ago, P <0.02) 
predicted the lower prevalence of EGFR mutations 
compared to smokers.68
A Japanese trial examined EGFR gene mutations 
within exons 18–21 and their correlations to 
clinico-pathological factors and other genetic 
alterations in 154 resected tumour specimens. 
EGFR mutations were observed in 39%, all of which 
were adenocarcinomas. Among the patients with 
adenocarcinoma, EGFR mutations were more 
frequently observed in non-smokers than former or 
current smokers (83%, 50% and 15.2%, respectively); 
in women than men (76.3% versus 34.0%); in 
tumours with a bronchioalveolar component than 
those without (78.9% versus 42.9%), and in well- to 
moderately-differentiated tumours compared to 
their poorly differentiated counterparts (72%, 64.4% 
and 34.2%, respectively). Tumours with EGFR 
mutations had no K-Ras codon 12 mutations, which 
remains a known tobacco carcinogen-induced 
mutation.69 
Patients who smoke have a lower chance of 
having an EGFR mutation (14%) and the vast 
majority harbour wild-type EGFR, failing to qualify 
them for targeted TKI therapy, while current 
smokers who do harbour the mutations have 
poorer RR, PFS, and OS despite TKIs. However, 
all categories harbouring EGFR mutations benefit 
from the targeted TKIs, irrespective of their 
smoking status.
Tobacco Smoke—A 
Prognostic and Predictive 
Characteristic
In an exploratory subgroup analyses of a trial 
using salvage erlotinib (first or second line), OS 
was markedly increased in never-smokers (<20% 
of patients) on both univariate (P <0.001) and 
multivariate (P 0.048) analyses as compared to ex-
smokers.70 In a retrospective review of 139 NSCLC 
patients at MSKCC, a multivariable analysis 
revealed that the presence of adenocarcinoma 
with any bronchioalveolar features (P 0.004), and 
being a never-smoker (P 0.006) were independent 
predictors of response.71
Retrospective analyses of IDEAL 1 and 2 studies 
reveal that never-smokers derive greater benefit 
from TKI therapy compared to ever-smokers.60,72 In 
a phase II Iressa Survival Evaluation in Lung Cancer 
(ISEL) study, a pre-planned subgroup analysis 
showed significantly longer survival in the gefitinib 
group than the placebo group for never-smokers 
(n = 375; median OS = 8.9 versus 6.1 months; 
P 0.012) in adenocarcinoma.61 A survival advantage 
for erlotinib compared with a placebo was 
demonstrated in the NCIC BR.21, a randomised, 
double-blind study of patients (n = 731) with 
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patient subgroups, the range for never-smokers 
was 65.8–100% and the EGFR mutation status was 
known in 33–100%. Activating somatic mutations 
were found in a high percentage in this subgroup 
(49–100%), and there was a consequent superior 
efficacy with TKIs.78
Erlotinib was compared alone or with carboplatin 
paclitaxel in never- or light former- smokers and 
showed similar efficacy, but TKI was less toxic in 
predominantly Caucasian never-smokers with 
advanced NSCLC.79 In a Brazilian study comprising 
of NSCLC patients (n = 285), the majority were 
ever-smokers (76%). Among the never-smokers 
(n = 56), there were significantly more women 
(68%) and adenocarcinoma subtypes (70%). The 
OS at 5 years of never-smokers and ever-smokers 
were significantly different (P 0.049). The median 
survival time was 14.9 months for ever-smokers 
and 22.1 months for never-smokers. Multivariate 
analysis of factors related to OS, using the Cox 
regression for never-smokers, was highly significant 
(HR 0.58; P 0.047) without any influence of female 
gender or adenocarcinoma.80 In a subgroup analysis 
of the Chinese OPTIMAL trial, the P value for the 
interaction test between various smoking statuses 
was 0.34, favouring the TKI in never-smokers.
On the contrary, a recent trial from western 
Japan (WTOG 3405) could not validate the 
effects of smoking status, age, sex, postoperative 
recurrence and mutation type on OS on univariate 
or multivariate analyses while comparing gefitinib 
to cisplatin and docetaxel chemotherapy.81 
A recently published trial of 1,725 patients, 
cisplatin and pemetrexed versus cisplatin and 
gemcitabine showed an interesting result among 
enrolled never-smokers who comprised 14–15% of 
the overall patient population. This trial showed that 
never-smokers had a superior median OS in both 
chemotherapy arms compared to current or former 
smokers (15.9 versus 10.0 months in the cisplatin 
and pemetrexed arm; 15.3 versus 10.3 months for 
the cisplatin and gemcitabine arm).82
The superior survival in the preceding trials, 
are attributable to higher EGFR mutation rates in 
never-smokers. Therefore, tobacco smoking has 
indirectly emerged as a good predictor for response 
to TKI and is generally associated with enhanced 
survival outcomes. 
advanced-stage NSCLC. A marginally significant 
interaction was observed between smoking history 
and treatment (P 0.054). The hazard ratios (HR) 
were 0.42 among never-smokers and 0.87 for 
smokers, indicating that erlotinib was beneficial 
irrespective of the smoking status, but the TKI was 
more useful in never-smokers. Patients with EGFR-
positive tumours who had never smoked derived 
the greatest survival benefit from erlotinib relative 
to a placebo (HR 0.28; P 0.0007).73
In an unselected NSCLC population in the 
TALENT and INTACT 1 and 2 studies, there 
was no benefit when erlotinib was combined 
concurrently with chemotherapy when compared 
to chemotherapy alone. It should be noted, however, 
that the endpoints of these studies were not meant 
for evaluating variables like smoking status.74,62,63 
However, in the TRIBUTE trial, the addition of 
erlotinib to chemotherapy when compared to 
chemotherapy plus a placebo did reveal a doubling 
in survival in 10% of the never-smokers of the 
subgroups. When compared with former or current 
smokers, the never-smokers were relatively younger, 
predominantly female, and frequently harboured 
adenocarcinoma. While the median OS of never-
smokers on a placebo was similar to that of current 
or former smokers on a placebo (~10 months), 
the never-smokers on erlotinib had a doubling of 
median survival (22.5 months), and an improved 
median time to progression (TTP) (6 versus 4.3 
months).75
A trial by Mok et al. was carried out primarily 
on never-smokers (EGFR mutations in 61%) or on 
light ex-smokers (EGFR mutations in 47%). Their 
IPASS trial used oral gefitinib and compared it to 
paclitaxel carboplatin in East Asian chemo-naive, 
never- or light ex-smokers (n = 261). The RR was 
71% with TKI and 43% with chemotherapy. The RR 
was 1% with TKI and halved with chemotherapy in 
wild-type EGFR. Patients with an EGFR mutation 
had a doubling in PFS with gefitinib, while in those 
having wild-type EGFR, the PFS almost tripled 
with chemotherapy.76 For never-smokers in the 
Caucasian EURTAC study, the median PFS was 9.7 
months in favour of erlotinib as compared to 5.1 
months with chemotherapy.77
In a review of 4 randomised trials of gefitinib as 
first-line therapy in advanced NSCLC, the majority 
of patients were women (63–88%) and had the 




Smoking has a multidimensional impact on lung 
cancer. It remains the most consistent causative 
agent for developing the disease and carries 
a definitive prognostic and predictive value. 
Adenocarcinoma is more common in never-
smokers and females. The rates for EGFR and 
EML4 ALK mutations are higher in never-smokers 
providing these individuals a chance for targeted 
therapy. However, TKIs are ineffective in smokers 
with K-Ras mutations. Therapy optimisations 
should be integral while planning therapy. There is 
enormous room for molecular profiling of never-
smokers where carcinogenesis stays presumptive. 
Smoking during a course of therapy remains 
detrimental, and patients should be advised to 
discontinue it as soon as possible. Strict regulations 
to control tobacco smoking can avert a number of 
human deaths globally, and lung cancer particularly. 
The fight between health authorities, the tobacco 
industry, and smokers continues to haunt humanity 
while the tobacco industry continues to pocket 
millions of USD in profit. 
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